Table 2

Treatment-related serious adverse events (AEs)

AEGrade AE in dose cohortGrade 3 and above
# affected/%
10 µg20 µg33 µg50 µg70 µg
ALP, high3, 3, 434/19.0
Dyspnea442/9.5
Potassium, high332/9.5
Soft tissue necrosis3*, 3*2/9.5
Acidosis31/4.7
ALT, high3*1/4.7
AST, high3*1/4.7
Dehydration41/4.7
Diarrhea31/4.7
Hypoxia41/4.7
Lethargy/fatigue31/4.7
Lymph leakage31/4.7
Peritonitis, non-septic31/4.7
Total5610719
  • *Attribution possibly related to treatment. All others attributed to disease progression.

  • ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase.